NovaMedica is in advanced negotiations to secure Russia and CIS rights for a wide range of innovative Products. We are seeking specialty pharmaceutical drugs and devices from various potential US and European partners (including Domain Associates, Inc. portfolio companies) spanning several high-growth therapeutic areas in hospital inpatient, hospital outpatient and specialty care clinical contexts. Products can be both FDA/EMA approved and phase 2B/3 late-stage development. Please check back regularly as we grow our pipeline to serve this exciting market.
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Grand finale from a veritable stalwart of neuroscience
09 November 2023
Battle of pharma advocates – in search of the ideal migraine therapy
09 November 2023
Positive study results in 298 patients with obstructive sleep apnea (OSA)
15 March 2024
Rapid pseudomonas aeruginosa detection method developed
15 March 2024
Developing new treatment regimens for HIV
14 March 2024
Life sci marketing budgets boomed in 2023, led by spending on trade shows and websites, survey finds
14 March 2024